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Parkinson’s disease (PD) is a common disorder, and the diagnosis of Parkinson’s disease is clinical and relies on the presence of
characteristic motorsymptoms. The accuracy of theclinical diagnosis of PD is stilllimited. Functional neuroimaging using SPECT
technique is helpful in patients with ﬁrst signs of parkinsonism. The changes detected may reﬂect the disease process itself and/or
compensatory responses to the disease, or they may arise in association with disease- and/or treatment-related complications.
This paper addresses the value of SPECT in early diﬀerential diagnosis of PD and its potential as a sensitive tool to assess the
pathophysiology and progression, as well as the therapeutic eﬃcacy of PD.
1.Introduction
PD is a common neurodegenerative disorder characterized
by the motor features of rigidity, tremors, akinesia, and cha-
nges in speech and gait which are associated with the loss of
dopaminergic neurons in the substantia nigra pars compacta
and the subsequent deﬁciency in striatal dopaminergic sys-
tem. It has prevalence of 1-2 per 1,000 among the general
p o p u l a t i o na n do fu pt o2 %a m o n gp e o p l ea g e do v e r6 5
years. Parkinson’s causes are unknown but genetics, aging,
andtoxinsarebeingresearched.Thepathophysiologicalhall-
mark of PD is a slow, progressive degeneration of the nigros-
triatal dopaminergic system. The widely accepted subcellular
factor which underlies PD neuropathology is the presence of
Lewy bodies [1] with characteristic inclusions of aggregated
alpha-synuclein [2–4]. A recent study revealed that PD spec-
iﬁc brain pathology extends far beyond the nigrostriatal do-
paminergic system and aﬀects widespread brain areas, in-
cludingtheolfactorysystem,autonomicandgainsettingbra-
instem nuclei, and the cerebral cortex [5]. Physiological
imaging techniques such as positron emission tomography
(PET) or SPECT provide the means for detecting in vivo me-
tabolic and neurochemical changes of PD.
Motorsymptomssuchastremoratrest,akinesia,rigidity,
and postural instability are the cardinal signs in PD [6]. The
type and severity of symptoms experienced by a person with
PD vary with each individual and the stage of the disease. PD
is the most common cause of parkinsonism. There are also
many nonmotor features of PD including behavioral and
psychiatric problems such as dementia [7], fatigue [8], an-
xiety [9] and depression [10], autonomic dysfunction [11],
addiction and compulsion [12], psychosis [13], olfactory dy-
sfunction[14],andcognitiveimpairment[10].Theseclinical
features also occur in other neurodegenerative diseases and
by dopamine receptor antagonist drugs, which means that
with this main clinical application it is hard to diagnose pa-
tients with mild, incomplete, or uncertain parkinsonism
[15]. The United Kingdom Parkinson’s Disease Society Brain
Bank clinical diagnostic criteria can improve diagnostic ac-
curacy [16]; still, the diagnosis and management of PD can
be a challenge.
The diagnosis of PD is based on clinical criteria, but mis-
diagnosis is as high as 25% of cases as conﬁrmed by an-
atomic-pathologic studies. Because the diagnosis of PD is
entirely clinical, the diagnosis and treatment may be delayed2 Journal of Biomedicine and Biotechnology
for years until functional disability occurs. SPECT is an aid
that can help diagnosing the disease earlier.
2. Imaging Agent of SPECT for PD
TheligandsusedforSPECTbelongtoagroupofcompounds
derived from cocaine that bind to the dopamine transporter
and include IPT, TRODAT-1, and FP-CIT tagged with either
iodine-123 (T1/2 = 13.2h) or technetium-99m (T1/2 =
6h) radioisotopes. Tracers used for SPECT imaging of PD
patients are presented in Table 1.
Speciﬁc SPECT ligands for DAT (FP-CIT, beta-CIT, IPT,
TRODAT-1) imaging provide a marker for presynaptic neur-
onal degeneration [17]. Postsynaptic receptor density is ex-
plored with dopamine receptor ligands, notably of the D2
type [18].
Unlike PET, there is no need for an on-site cyclotron or
for radiochemistry facilities due to a longer half-life. SPECT
studies have the advantage of using an industrial production
of tracers. The reduced cost of radiotracer synthesis permits
the investigation of a larger number of patients by SPECT
than by PET.
123I-β-CIT. 123I-β-CIT is a radiotracer which binds with na-
nomolar aﬃnity to the serotonin transporter. It has a pro-
tracted period of striatal uptake enabling imaging 14–24
h o u r sa f t e ri n j e c t i o nf o rs t a b l eq u a n t i t a t i v em e a s u r e so fd o p -
amine transporters [19].
123I-FP-CIT. 123I-FP-CIT is an analogue of 123I-β-CIT. It has
been shown to achieve peak tracer uptake in the brain within
hours after injection and to provide greater selectivity for the
dopamine transporter. 123I-FP-CIT washed out from striatal
tissue is 15–20 times faster than that of 123I-β-CIT [19]. A
clear decline in 123I-FP-CIT binding was found with aging,
amounting to 9.6%/decade in the control group [20].
123I-IPT. 123I-IPT is a new cocaine analogue which allows
the presynaptic dopamine transporters to be imaged with
SPECT as early as 1-2h after injection [21].
125I/123I-PE21. P E 2 I ,ac o c a i n ed e r i v a t i v e ,h a sg o o da ﬃnity
for the DAT. 125I-PE2I has revealed very intense and selective
binding in the basal ganglia [22]. It is a highly potent inhibi-
tor of cloned DAT compared with GBR 12935 and pro-
vided a useful tool for further investigations in cells trans-
fected with cDNA encoding the DAT [23]. PE2I is a relatively
new radioligand that has about 10-fold higher in vitro
selectivity for the DAT than for the serotonin transporter
(SERT)comparedto 123I-FP-CIT[24].Further, 123I-PE2Ihas
faster kinetics than 123I-FP-CIT. It is currently to be con-
sidered the best radioligand for imaging the DAT in the hu-
man brain with SPECT.
99Tcm-TRODAT-1. 99Tcm-TRODAT-1 is a recently devel-
oped radiotracer that selectively binds to the dopamine tran-
sporters, which are signiﬁcant because loss of these trans-
porters corresponds with a loss of dopaminergic neurons. It
is a potential agent for DAT SPECT [25].
















(postsynaptic dopamine D2 receptor)
123I-Iodolisuride, 123I-IBF,
123I-Epidepride (extrastriatal DA receptors)
123I-IBZM. 123I-IBZM is a central nervous system (CNS) D-
2 dopamine receptor imaging agent, and it has a high con-
centration in basal ganglia of brain [26].
123I-IBF. 123I-IBF is an IBZM analogue. This agent concen-
tratedinthestriatumregionanddisplayedaremarkablyhigh
target-to-nontarget ratio [27] and early time of peak uptake
[28]. A study using P450 gene expression systems indicates
that 123I-IBF is enzymatically metabolized in the liver and
rapidly excreted in the urine [29]. It is a potential agent for
imaging D-2 dopamine receptors [30].
3. The Use of SPECTMolecularImaginginPD
3.1. The Course and the Pathogenesis of PD. Brain SPECT
imaging of DAT with speciﬁc radioligands provides a useful
tool of in vivo investigation of the pathogenesis of PD, and it
isasensitivemethodforexaminingtheintegrityofthepresy-
naptic dopaminergic system [15]. Cerebral and extracranial
Lewy-body-type degeneration in PD does not develops inde-
pendently from each other but develop in a strongly coupled
manner. The cerebral and extracranial changes are driven by
atleastsimilarpathomechanisms[31].PatientswithPDhave
markedly reduced DAT levels in striatum, which correlated
with disease severity and disease progression [32], whereas
postsynaptic striatal D2 receptors are upregulated [33]. Sim-
ilarly, another study reported that the mean 123I-IBZM
striatal-occipital ratio of binding was signiﬁcantly higher in
PD patients than in controls. In PD patients, higher values
were found contralateral to the clinically most aﬀected side,
suggestingD2receptorupregulationandthereversewasseen
using 123I-FP-CIT SPECT [34]. Dual isotope imaging using
99Tcm-TRODAT-1 and 123I-IBZM is also a useful means in
evaluating the changes of both pre- and postsynaptic dopa-
mine system in a primate model of parkinsonism [35].
There was a signiﬁcant association of visually analyzed
shapesofthestriatuminFP-CITSPECTandclinicalPDsub-
type. It suggested that factors other than nigrostriatal de-
generationmaycontributetodiseaseseverity[36].Onestud-
y including 122 patients conﬁrmed neuropathological mod-
els for reduced dopaminergic projection to the dorsal puta-
men in akinetic-rigid patients as well as the lateral putamenJournal of Biomedicine and Biotechnology 3
Healthy control subject
(a)
Patient with early Parkinson’s disease
(b)
Figure 1: TRODAT-1 SPECT images of a healthy control (a) and a patient with early PD (b). The patient with early PD shows decreased
TRODAT-1 uptake in the striatum compared to the control, particularly in the posterior putamen [45].
and caudate nucleus in tremor-dominant patients in vivo
[37], and the serotonergic system is suggested to be impli-
cated in PD [38]. Furthermore, another study showed that
SERT-dependent 123I-FP-CIT uptake may allow a more com-
prehensive assessment of neurochemical disturbances in de-
generative parkinsonisms [39]; this study suggested that the
neurodegenerative process extends beyond nigrostriatal sys-
tem and aﬀects serotoninergic neurons in parkinsonisms.
3.2. Early Diagnosis of PD. Since the in vivo molecular imag-
ing techniques using SPECT have been introduced, the diag-
nosis of PD became more reliable by assessing dopaminergic
and even nondopaminergic systems. SPECT is a very sen-
sitive technique to detect nigrostriatal degeneration in PD.
Various radiotracers have been used in the diagnosis of PD.
DAT imaging is abnormal even in the earliest clinical pre-
sentation of PD [15]. A study using 123I-β-CIT found that
the relative uptake reduction in the hemi-PD patients was
greater in the putamen than in the caudate in patients with
earlyPDandsuggestedthatitmaybeusefulinidentifyingin-
dividuals with developing dopaminergic pathology before
onset of motor symptoms [40].
It was reported that 123I-β-CIT SPECT was 100% sensi-
tive and speciﬁc for the diagnosis in younger patients (age
<55 years). In older patients (age >55 years), speciﬁcity was
substantially lower (68.5%) [41]. More recently, a prospec-
tive,longitudinalstudyusing 123I-FP-CIThadinvestigated99
patients with tremor and/or parkinsonism over 3 years, and
the results showed a mean sensitivity of 78% and a speciﬁcity
of97%[42].A2-yearfollowed-upSPECTstudyusing 99Tcm-
TRODAT-1 was performed in patients with clinically unclear
Parkinsonian syndromes (CUPSs) and found that the rate
of disagreement of SPECT in the patients was of 20%. The
sensitivity of this technique was 100%, and speciﬁcity was
70%. It indicated that TRODAT-1 helps the diagnosis of
patients with CUPS [43]. DAT SPECT is sensitive enough
to detect a loss of nigrostriatal neurons in vivo even in pre-
clinical phases of sporadic PD.
123I-FP-CIT SPECT has been successfully used to detect
the loss of dopaminergic nigrostriatal neurons in Parkinson’s
diseaseatanearlystage.Buttheresultsreportedwerecontro-
versial. Tissingh et al. reported that striatal 123I-FP-CIT up-
take is markedly decreased in PD, more in the putamen than
in the caudate nucleus, and the mean reduction in the puta-
men and caudate nucleus was 57% and 29% of the control
mean, respectively. However, no signiﬁcant correlations were
found between striatal 123I-FP-CIT binding ratios and dis-
easeseverity [20].Spiegel et al.found thatthestriatalFP-CIT
binding correlated signiﬁcantly with the motor part of the
uniﬁed Parkinson’s disease rating scale (UPDRS) but not
with age, disease duration, or gender [44]. Another study
indicated that in patients with PD,the striatum, caudate,and
putamen uptake was correlated with disease severity assessed
by UPDRS and duration of disease [36]. More studies are
needed to conﬁrm these ﬁndings.
99Tcm-TRODAT-1 study including 29 patients with early
PD and 38 healthy volunteers found that compared to con-
trols, the uptake in caudate and anterior and posterior puta-
men values were signiﬁcantly decreased in PD patients
(Figure 1). Using the posterior putamen as the main region
of interest resulted in the greatest accuracy sensitivity 79%
and speciﬁcity 92% [45]. Patients with unilateral PD showed
a bilateral loss of striatal DA transporters [46]. A study using
semiquantitative 123I-FP-CIT SPECT detected a bilateral
dopaminergic deﬁcit in early PD with unilateral symptoms
and preclinical DAT loss in the ipsilateral striatal binding,
corresponding to the side not yet aﬀected by motor signs.
It suggested that semi-quantitative analysis may be used to
diagnose PD at early stage as well as to identify individuals
developing bilateral dopaminergic damage [47]. The de-
crease of striatal uptake contralateral to the more aﬀected
side of the body was more prominent compared to the ip–
silateral side [48]. Moreover, another study showed a sig-
niﬁcant loss of putaminal uptake ipsilateral to the symp-
toms was found in the stage I group compared with the heal–
thy volunteers [49]. The mean reduction of binding was
f o u n di nt h eo r d e ro fp u t a m e na n dc a u d a t en u c l e u s .
DAT imaging is a sensitive method to detect presynaptic
dopamine neuronal dysfunction. Normal DAT-SPECT can
be used to exclude underlying true nigrostriatal dysfunction
[50].
SPECT also contributes to the assessment of the non-
motor symptoms of PD. MIBG was used in the diagnosis
of damaged tissue of the heart. However, Sawada et al. [43]
found that a reduction in MIBG cardiac accumulation re-




Figure 2: Transverse 123I-β-CIT images. (a) The image from a
healthy control. (b) in PD patient the uptake is markedly reduced,
with putamen more aﬀected than caudate, and the right striatum
(opposite to the side of more severe symptoms) showing the largest
dopamine transporter (DAT) loss. (c) In MSA-striatonigral degen-
eration (MSA-SND) patient, the uptake is signiﬁcantly reduced
in both caudate and putamen and indicates more symmetric loss
of DAT. (d) In the MSA-Shy-Drager syndrome (SDS) patient, the
uptake is also signiﬁcantly reduced, with putamen more aﬀected
than caudate; the loss of DAT appears to be symmetric [64].
early and delayed images showed that the heart to me-
diastinum ratios were signiﬁcantly lower in the PD group
than in the non-PD group [51].
Sakakibara et al. [52] ﬁrst reported the correlation of
urinary dysfunction with nigrostriatal dopaminergic deﬁcit
in PD, which was studied by 123I-β-CIT SPECT. The tracer
uptake in patients with urinary dysfunction was signiﬁcantly
reduced than in those without urinary dysfunction
3.3. Diﬀerential Diagnosis of PD. Clinical features of PD
may be shared with other disorders; thus, the diﬀerential
diagnosis of PD is extensive. Idiopathic Parkinson’s disease is
associated with Lewy body degeneration of nigrostriatal do-
paminergic neurons [53]. Atypical parkinsonian syndromes
(APSs) such as multiple system atrophy (MSA), progressive
supranuclear palsy (PSP), and corticobasal degeneration are
characterized by poor response to antiparkinsonian me-
dication and rapid clinical deterioration, which one often
confused with PD. Other diseases, for example, drug-induc-
edparkinsonism(DIP),essentialtremor(ET),vascularpark-
insonism (VP), or Dementia with Lewy bodies (DLBs) may
also share common features with PD.
ET is a slowly progressive neurological disorder. DIP is
developed when patients are treated with neuroleptic or do-
pamine receptor blocking agents. In most patients, Parkin-
sonism is reversible upon stopping the oﬀending drug,
though it may take several months to resolve fully but in
some patients it may even persist. The diﬀerentiation be-
tween PD and DIP is diﬃcult to assess on clinical grounds
alone.
Functional imaging of the DAT deﬁnes integrity of the
dopaminergic system, and a normal scan suggests an alter-
native diagnosis such as ET, VP (unless there is focal basal
ganglia infarction), DIP, or psychogenic parkinsonism [17,
54]. Furthermore, a semiquantitative analysis with a cut-oﬀ
ofstriatalasymmetryindexgreaterthan14.08coulddiﬀeren-
tiate PD from VP with a 100% speciﬁcity [55]. 123I-FP-CIT
SPECT images demonstrate that SPECT imaging with DAT
ligands is useful to determine whether parkinsonism is en-
tirely drug induced [56] and showed high levels of accuracy
[57]. Cuberas-Borr´ os et al. performed FP-CIT images in 3
diﬀerent groups of ET, DIP, and PD patients. Lower up-
take was found in the PD group in comparison with the ET
and DIP groups both in the putamen and in the caudate
nucleus,butthediﬀerencesbetweenDIPandETpopulations
were only found in the putamen. There was an optimal
discrimination threshold value between the reference pop-
ulation and the pathologic population for the putamen ratio
by using volumes of interests, (VOIs) analysis [58].
SERT-dependent 123I-FP-CIT imaging showed a mild
decrease in SERT levels in PD compared to ET and health
control, and reduced to undetectable levels of SERT in PSP
and DLB patients were displayed markedly [39]. To improve
diagnostic accuracy, non-DAT tracers (i.e., D2 dopamine re-
ceptors) are necessary together with long-term clinical fol-
low-up and rescans [59].
MSA is a neurodegenerative disorder characterized by
neuropathologic demonstration of CNS alpha-synuclein-
positive glial cytoplasmic inclusions with neurodegenerative
changes in striatonigral or olivopontocerebellar structures
[60]. Clinically, MSA is characterized by autonomic dysfunc-
tion and/or urinary dysfunction which may be associated
with parkinsonian symptoms in 80% of patients (MSA-P)
or with cerebellar ataxia in 20% of patients (MSA-C). It is
diﬃcult to diﬀerentiate it from other movement disorders,
particularly in the early course of disease. Voxel wise analysis
of 123I-β-CIT SPECT revealed more widespread decline of
monoaminergic transporter availability in MSA-P compared
with idiopathic Parkinson’s disease (IPD) [61], matching
the underlying pathological features. They suggest that the
quantiﬁcation of midbrain DAT signal should be included in
the routine clinical analysis of 123I-β-CIT SPECT in patients
with uncertain parkinsonism.
A combined 99mTc-ECD/123I-FP-CIT brain SPECT pro-
tocols have been proven to improve the diﬀerential diagnosis
o fI P Da n dM S Aa sw e l la sc o r t i c o b a s a ld e g e n e r a t i o na n d
PSP [62]. SPECT with the tracer 123I-Ioﬂupane can also give
an accurate and highly sensitive measure of dopamine de-
generation [63].
Astudyshowedthatthedegreeoflosswashigherinputa-
men than caudate in both PD and MSA patients. However,
MSA patients showed a more symmetric loss (ipsilateral ver-
sus contralateral side) of striatal DAT in both caudate and
putamen than PD patients (Figure 2)[ 64]. It was also re-
ported that patients with a side-to-side diﬀerence of reduced
striatal 123I-β-CIT binding greater than 15% are likely to suf-
fer from IPD, while the patients with the diﬀerence be-
t w e e n5 %a n d1 5 %a r em o r el i k e l yt oh a v eM S A[ 65]. An-
other study showed that mean distribution volume ratios
(DVRs) in the basal ganglia of MSA patients were signiﬁcan-
tly less than in controls, but generally higher than in PD pa-
tients. Furthermore, the MSA patients had signiﬁcantlyJournal of Biomedicine and Biotechnology 5
increasedDVRsintheposteriorputamen(mean0.49 ±0.30)
compared with PD patients (0.74 ± 0.25) [66].
Anotherstudywhichusedboth 123I-β-CIT(forDAT)and
123I-IBF (for D2) reported that DAT binding in the posterior
putamen was markedly reduced in all patients. However, D2
binding in posterior putamen was signiﬁcantly increased in
dopa-untreated PD, and it was signiﬁcantly reduced in MSA.
These ﬁndings suggested that DAT SPECT may be useful in
diﬀerentiating parkinsonism from controls and D2 SPECT
in further diﬀerentiating MSA from PD [67]. IBZM SPECT
using recently introduced three dimensional automated
quantiﬁcation method calculating the Striatal/frontal cortex
binding ratios [68] and voxel-by-voxel binding potential pa-
rametric imaging also can discriminate among extrapyrami-
dal diseases such as PD and PSP [69].
123I-IBZM SPECT is an eﬀective diagnostic tool in the
establishment of the diﬀerential diagnosis in patients with
PD and Parkinson-plus syndromes. Quantiﬁcation of these
studies had limited utility since the overlapping of index va-
lues between normal and pathological restricts their use in
individual cases [70]. Vlaar et al. reported that FP-CIT
SPECT is accurate to diﬀerentiate patients with IPD from
those with ET, and IPD from VP and DIP, but the accuracy
of both FP-CIT and IBZM SPECT scans to diﬀerentiate be-
tween IPD and APS is low [54]. However, a study sug-
gested that using multidimensional combination of FP-CIT,
IBZM, and MIBG scintigraphy was likely to signiﬁcantly
increase test accuracy (94%) in diﬀerentiating PD from APS
[71]. More recently, a study using 123I-PE21 indicated that
dopamine transporter scan has a high sensitivity and speci-
ﬁcity in distinguishing between patients with and without
striatal neurodegeneration. Calculation of the striatal an-
terior-posterior ratio can assist in diﬀerentiating between
idiopathic PD and APS [72]. Moreover, study with 123I-FP-
CIT in165 patients with a clinical diagnosis of PD (n = 120)
or APS (n = 45) suggested that a global and severe degen-
eration pattern had a high positive predictive value of APS
within the ﬁrst 5 years of the disease [73].
A 123I-FP-CIT and 123I-IBZM SPECT study, in which
seven subjects were all from a Spanish family with G309D
mutation in the PINK1 gene, showed that striatal DAT bind-
ingwasreducedinallthreePARK6patients.Butintwoofthe
siblings, DAT binding was markedly increased. It suggested
that the increased DAT binding may be an early preclinical
ﬁnding [74]. SPECT is also useful for distinguishing PD
from Dopa responsive dystonia (DRD), or for assessing the
integrity of the nigrostriatal dopaminergic pathway in atyp-
ical cases of postural tremor or iatrogenic parkinsonian syn-
dromes.Theimagingwith 99Tcm-TRODAT-1/123I-IBZMina
39-year-old woman with a 24-year history of DRD indicated
that 99Tcm-TRODAT-1 is helpful in diﬀerentiating DRD
fromearly-onsetidiopathic parkinsonismandthe 123I-IBZM
SPECT is also helpful in diﬀerentiating these two conditions
in the later clinical course [75].
In IPD, two diﬀerent clinical phenotypes are usually dis-
tinguished: a tremor-dominant variant (TD) and an aki-
netic-rigid type (ART). TD patients compared to ART pa-
tients are characterized by a slower disease progression and
a minor cognitive impairment. For diﬀerent phenotypes of
PD, 123I-FP-CIT SPECT has indicated that the dopaminergic
system in ART patients is more involved compared to that in
the TD patients and that this kind of diﬀerence is present
from the initial stage of the disease [76–78]. There was a
signiﬁcantly higher FP-CIT uptake in contralateral putamen
and a higher but not statistically signiﬁcant uptake in all the
other striatal regions in TD patients when compared to ART
patients [77]. Similarly, Spiegel et al. reported a greater im-
pairmentinARTpatientsinallstriatalregionsanalyzed[78].
These results suggest that further systems besides the nigro-
striataldopaminergicsystemmaycontributetogenerationof
parkinsonian tremor.
3.4. Monitoring the Progression of the PD. Pathologic studies
investigating the rate of PD progression have been limited to
patients with severe illness of long duration and rely entirely
oncross-sectionaldata.TheUPDRSorotherfunctionalclin-
ical endpoints are used to monitor disease progression. It
makes it diﬃcult to isolate clinical change solely due to dis-
ease progression [79].
The rate of progression of dopaminergic degeneration is
much faster in PD than in normal aging [80]. Patients with
P Dp r e s e n tﬁ r s tw i t hu n i l a t e r a ls y m p t o m st h a tg r a d u a l l y
progress to involve both sides [6]. Clinical progression has
been investigated with SPECT, which could prove to be an
objective tool for monitoring the disease progression.
123I-β-CIT SPECT imaging of the dopamine transporter
is a sensitive biomarker of PD onset and severity. A group of
50 early-stage PD patients was examined [81]. Two SPECT
imaging series were obtained 12 months apart. The average
decrease in 123I-β-CIT binding ratios was about 8% in the
whole striatum, 8% in the putaminal region, and 4% in the
caudateregion.Thisﬁndingsupportedthefeasibilityofusing
123I-β-CIT in the evaluation of disease progression in PD
[82]. Moreover, sequential SPECT scans using 123I-β-CIT
in PD subjects demonstrated a decline in striatal uptake of
approximately 11.2%/year from the baseline scan, compared
with 0.8%/year in the healthy controls [79]. Another SPECT
study with 123I-β-CIT demonstrated a rapid decline of
striatalbindinginpatientswithAPS,exceedingthereduction
inPD,andthedopaminergicdegenerationinPDslowsdown
during the course of the disease [83].
Combined 123I-β-CIT and 123I-IBZM SPECT studies
have demonstrated that postsynaptic dopamine receptor up-
regulation contralateral to the presenting side occurs in
untreated unilateral PD and disappears in untreated bilateral
(asymmetric) PD despite a greater loss of dopamine trans-
porter function [84]. This may be helpful in monitoring the
progression of nigrostriatal dysfunction in early PD. Tatsch
et al. [21] found that speciﬁc 123I-IPT uptake in the caudate
and putamen, and putamen to caudate ratios, decreased
with increasing Hoehn and Yahr stage (H-Y). These ﬁndings
indicatedthat 123I-IPTSPECTalsomaybeausefultechnique
to estimate the extent of nigrostriatal degeneration in PD pa-
tients.
Tissingh et al. reported that disease severity correlated
negatively and highly signiﬁcantly with the 123I-β-CIT bind-
ing in patients with early PD. Tremor ratings did not cor-6 Journal of Biomedicine and Biotechnology
relate with the 123I-β-CIT uptake, whereas rigidity and
bradykinesia did [46]. The striatal 123I-β-CIT uptake in a
large cohort of PD subjects signiﬁcantly correlated with se-
verity of PD as measured by UPDRS [79]. The mean reduc-
tion of 99Tcm-TRODAT-1 uptake was found in the order of
putamen (contralateral side, −81%; ipsilateral side, −67%)
and caudate nucleus (contralateral side, −46%; ipsilateral
side, −40%), and it correlated negatively with the UPDRS
and H-Y staging [85].
Winogrodzka et al. [80] used 123I-FP-CIT SPECT for
the assessment of the rate of dopaminergic degeneration in
PD. The mean annual decrease in striatal binding ratios in
PD patients was found to be about 8% of the baseline mean,
indicating that 123I-FP-CIT SPECT was applicable to inves-
tigate the progression of dopaminergic degeneration. The
speciﬁc to nonspeciﬁc 123I-FP-CIT uptake ratios were calcu-
lated for striatum, caudate, and putamen, all of which were
correlated with disease severity assessed by UPDRS and the
duration of disease, suggesting that tremor may origins from
other systems instead of the dopamine transporter system.
Meanwhile, these ratios correlated with the bradykinesia
subscore but not with rigidity or tremor subscore. It sug-
gested that factors other than nigrostriatal degeneration may
contribute to disease severity [36].
3.5. Evaluation of the Treatment Eﬀect of PD. Current thera-
pies include drug therapy, surgical procedures, and stem cell
transplantation.DrugtherapysuchasDAreplacementthera-
py with levodopa fails to prevent the progression of the dis-
ease process and only alleviates the clinical symptoms. Once
the diagnosis is made, the neurologist with the patient must
decide whether to institute treatment at the time of diagnosis
or when functional disability occurs [86]. To evaluate the
eﬀectiveness of treatment, it is critical to develop methods
that can reliably measure the progression of dopaminergic
degeneration.
Postsynaptic imaging has been helpful in predicting
thera-peutic response to dopaminergic medication early in
the course of Parkinson’s disease. Studies have demonstrated
that PD patients receiving treatment do better than those
whodonot,andthosereceivingtreatmentearlierdobetterin
longterm[87].Schwarzetal.performedafollow-upstudyof
2–4 years including 55 patients with parkinsonism and prior
dopaminomimetic therapy and found that IBZM-SPECT
accurately predicted the response to apomorphine and
levodopa, The sensitivity/speciﬁcity was 96.3%/64.7%, and
100%/75% [88]. Thus, 123I-IBZM can be used routinely to
identify which PD patients will beneﬁt from dopaminergic
medication [89]. Another study including 20 PD patients
who undergone short-term levodopa test and SPECT imag-
ing found there was a relationship between responsiveness
to levodopa and asymmetry detected with 123I-FP-CIT. This
technique can predict dopaminergic responsiveness in
patients with PD [90].
Recently, a 99Tcm-TRODAT-1SPECTindicatedthatlevo-
dopa did not interfere with DAT binding, suggesting that dif-
ferencesbetweenclinicalassessmentandradiotracerimaging
in clinical trials may not be speciﬁcally related to levodopa
treatment [91]. Similarly, the eﬀect of subchronic treatment
on striatal DAT was examined in patients who were not cur-
rently being treated with these medications. These results
suggested that typical clinical doses of levodopa/carbidopa
and L-selegiline did not induce signiﬁcant occupancy of the
123I-β-CIT binding site and that 4–6 weeks of treatment
causednosigniﬁcantmodulationofDATlevels.Theseresults
supported the validity of measuring DAT levels with 123I-β-
CIT without the need to withdraw patients from medication
treatment [92]. 123I-β-CIT SPECT imaging provides a quan-
titative biomarker for the progressive nigrostriatal dopa-
minergic degeneration in PD. As new protective and restora-
tive therapies for PD are developed, dopamine transporter
imaging oﬀers the potential to provide an objective endpoint
for these therapeutic trials [79, 80].
Hwang et al. found that the PD patients with ﬂuctuating
levodopa response showed a signiﬁcant decrease in 123I-
IBZM uptake (D2 receptor densities) than early levodopa-
naivePDandchronicPDwithstablelevodoparesponse[93],
which contributed to the development of motor ﬂuctuation.
4. Discussion
It has been reported that PET using 18F-dopa represents a
useful tool for detecting a reduction of dopaminergic activity
in PD patients at a very early stage [94, 95]. But the uptake
might be upregulated in the early phase of the disease where-
as expression of DATs might be down-regulated. SPECT
imaging combining both pre- and postsynaptic study as well
as clinical criteria improves the diagnosis of early Parkinson’s
disease. The quantitative combination of presynaptic DAT
and postsynaptic D2 receptor binding demonstrated higher
diagnostic accuracy in the diﬀerentiation of patients with PD
from patients with nonidiopathic parkinsonian syndromes
than the established approach based on striatal D2 receptor
binding alone [96].
The imaging of DAT with 99Tcm-TRODAT-1 SPECT has
beenrecentlyproposedtobeavaluableandfeasiblemeansof
assessment of the integrity of dopamine neurons [45]. 123I-
FP-CIT also has been successfully used to detect the loss of
dopaminergic nigrostriatal neuron in PD at an early stage
[47]. The sensitivity and speciﬁcity of this technique were
100% in discriminating PD patients from healthy subjects in
theage-speciﬁc(>50y)groups[85].Abilaterallossofstriatal
DA transporters in patients with unilateral PD suggests that
it may identify subjects in the preclinical phase of the disease.
There was a continuous reduction in speciﬁc striatal up-
takeespeciallyfortheputaminaluptakeof 99Tcm-TRODAT-1
with increasing disease severity in Parkinson’s disease pa-
tients. In PD patients, presynaptic neurodegeneration may
aﬀect the putamen and caudate with diﬀerent severity [20];
however,therewerenosigniﬁcantcorrelationsbetweenstria-
tal 123I-FP-CIT binding ratios and disease severity as were
established earlier with 99Tcm-TRODAT-1. Further research
is necessary to interpret these ﬁndings.
The putaminal uptake contralateral to the more aﬀected
limbs was signiﬁcantly reduced compared with the ipsilater-
al sides and the diﬀerence became greater when the poste-
rior putaminal uptakes were compared [49], and the dis-
criminant function analysis of both the ipsilateral and con-Journal of Biomedicine and Biotechnology 7
tralateral putamen classiﬁed 100% of their patients correctly,
whereas analysis using only the contralateral putamen clas-
siﬁed 92% of cases correctly [46]. PET imaging using 18F-
DOPA also demonstrated a signiﬁcant abnormality in the
posterior putamen of PD patients [97]. In conclusion, the
analysis using the mean of the ipsilateral and contralateral
posterior putamen may result in the greatest accuracy.
The study conﬁrms asymmetric D2 receptor upregula-
tion in PD. However, the sensitivity of contralateral higher
striatal 123I-IBZM binding is only not so obvious, therefore,
PDcannotbeexcludedinpatientswithparkinsonismandno
contralateral upregulation of D2 receptors [34]. The exact
diagnostic accuracy of this technique in parkinsonian syn-
dromes remains controversial.
MSA and PD patients are diﬃcult to diﬀerentiate from
each other. Imaging studies using diﬀerent dopamine trans-
porters in MSA patients have reported same results: DAT
binding wassigniﬁcantlydecreasedinallregions inboth IPD
and MSA patients as compared with healthy subjects. A
s t u d yb yu s i n g123I-β-CIT SPECT demonstrated that the
posteriorputamenismoreinvolvedthanthecaudateinMSA
[67]. Another study using 99Tcm-TRODAT-1 showed MSA
patients had signiﬁcantly higher tracer uptake particularly
in the posterior putamen compared with PD patients and
signiﬁcantly lower uptake compared with controls. The re-
sult suggested that the two neurodegenerative diseases have
diﬀerent pathophysiological processes [66].
Al a r g er e t r o s p e c t i v es t u d y[ 54] on the diagnostic value
of the FP-CIT and IBZM SPECT scan in patients with park-
insonian symptoms of unknown origin concluded that FP-
CIT SPECT is accurate to diﬀerentiate patients with IPD
from those with ET, and IPD from VP and DIP, but the two
scanshadlowaccuracytodiﬀerentiatebetweenIPDandAPS.
Ageisthelargestriskfactorforthedevelopmentandpro-
gression of PD [98]. PD may reﬂect a failure of the normal
cellular compensatory mechanisms in vulnerable brain reg-
ions, and this vulnerability is increased by ageing. PD is one
of the best examples of an age-related disease. Presynaptic
imaging has demonstrated the ability to objectively measure
the progression of Parkinson’s disease. Although the rate of
progression of the dopaminergic terminal loss in patients
with PD was correlated with clinical severity, the annual
percentage loss of 123I-β-CIT striatal uptake did not correlate
with the annual loss in measures of clinical function [79].
Striatal 123I-IPT uptake was closely related to the stage of PD.
The binding ratios decreased markedly from H-Y stage I to
stage IV; in addition, this imaging technique has a special
advantage that data can be acquired within a few hours after
injection [21]. The rate of progression may be faster in APS
than in PD [83]. To interprete the results well, caution
must be paid in the studies in which therapeutic eﬀects in
Parkinson’s disease were also monitored by serial imaging of
nigrostriatal neurons [99].
For diﬀerent phenotype of PD, FP-CIT striatal uptake
values signiﬁcantly correlated with bradykinesia and rigidity
but not with tremor [78], putaminal relative sparing in TD
patients could partially contribute to the slower disease pro-
gression.Thisfactcouldexplainthediﬀerentdiseaseprogres-
sion with a more benign course in TD group. A widespread
degeneration of the nigrostriatal dopaminergic pathway
might be necessary for the development of parkinsonian tre-
mor at rest [100].
Early Parkinson’s disease is dominated by a motor syn-
drome called parkinsonism, but as the disease develops mo-
torcomplicationsandnonmotorproblemsmayoccuraswell
[6].
The results of imaging of dopamine-D2 receptors with
the improvement in motor signs by the injection of apomor-
phine and oral dopaminomimetic therapy were compared
[88]. It can be concluded that normal IBZM binding is a use-
fulpredictorofagoodresponsetodopaminergicdrugsinPD
patients and a questionable response to previous dopamin-
omimetic therapy. However, reduced IBZM binding seems
to exclude a diagnosis of PD but suggests another dis-
order of the basal ganglia.
To evaluate eﬀectoftreatmentwithdrugsonstriatalDAT,
the imaging was performed before treatment, while on med-
ication, and following withdrawal from medication in each
patient.Thus,theresultsprovidedameasurementofDATle-
vels and drug occupancy following subchronic drug treat-
ment and drug occupancy of the tracer binding site [92].
Semiquantiﬁcationofstriataluptakeismorecorrectthan
visual reading, but it is also time consuming and prone to
error, particularly if the VOIs are positioned manually. There
is a critical need to create a new technique to solve this prob-
lem. A new software tool (“IBZM tool”) was presented for
fully automated and standardized processing, evaluating and
documenting the 123I-IBZM SPECT scans [101].
MIBG may be a peripheral biological marker of PD in-
cluding triplication of the a-synuclein gene. Although diag-
nostic accuracy of cardiac MIBG scintigram in PD is high,
the sensitivity is insuﬃcient in patients with short duration
[43]. Because of its relatively lower sensitivity, cardiac 123I-
MIBG scintigraphy is of limited value in the diagnosis of
early PD. However, because of its high speciﬁcity, it may
assist in the diagnosis of PD [51]. Furthermore, Fukuyama
[102] analyzed the reports about MIBG imaging in PD, and
suggested that it should not be regarded as the ﬁrst and best
choice of diagnostic aid for PD, especially in the early stages,
and careful attention should be paid for diagnosis of PD or
diﬀused Lewy body disease.
A study showed there is an association between urinary
dysfunction and degeneration of the nigrostriatal dopamin-
ergic cells in PD [52]. The results may promote further stud-
ies of dopaminergic drug treatments on urinary dysfunction
in PD.
5.Perspective
SPECT imaging has proven to be a useful tool to investigate
the many facets of PD in vivo. This technique helps under-
stand the pathogenesis, the diﬀerential diagnosis, and the
progression of the PD.
The disadvantage of SPECT compared to PET is that it is
diﬃcult to obtain a reliable quantiﬁcation. Furthermore, the
resolution of images is a limitation for the visualization of
basal ganglia in PD. However, SPECT is more practical as a
routine procedure than PET. In the future, the technique8 Journal of Biomedicine and Biotechnology
that provides high accuracy and new radiotracers needs to
be developed to help understand the role of non-DA neuro-
transmitter systems in PD.
SPECTcombinedwithothertechniquessuchastranscra-
nial sonography and olfaction test may have a higher accu-
racy in the diagnosis of PD. Imaging agents like dopamine
transporter or D2 receptor ligands assess only part of aspects
ofthedopamineneurons.Newtracersneedtobesynthesized
to detect other aspects of dopamine neurons.
The SPECT imaging of the nigrostriatal dopaminergic
pathwaycanbeusedtomonitortherapeuticeﬀectsinParkin-
son’s disease. As new protective and restorative therapies for
PD are developed, dopamine transporter imaging oﬀers the
potential to provide an objective endpoint for these thera-
peutic trials. Further studies are needed to evaluate the pos-
sible eﬀects of the therapy, especially for the delayed-onset
bilateral symptoms. Moreover, there is a pressing need to
improve our understanding ofthe pathogenesis to enablede-
velopment of disease modifying treatments.
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